Detalhe da pesquisa
1.
CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors.
Cancer Immunol Immunother
; 73(2): 36, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38280003
2.
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.
Br J Cancer
; 128(8): 1418-1428, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36797356
3.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Br J Cancer
; 129(5): 797-810, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37474720
4.
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Int J Gynecol Cancer
; 32(1): 93-100, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34799418
5.
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
J Pathol
; 241(3): 362-374, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27859259
6.
International consensus guidelines for scoring the histopathological growth patterns of liver metastasis.
Br J Cancer
; 117(10): 1427-1441, 2017 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28982110
7.
Mechanism of tumour vascularization in experimental lung metastases.
J Pathol
; 235(3): 384-96, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25319725
8.
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
J Immunother Cancer
; 12(4)2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38642937
9.
A gut microbial signature for combination immune checkpoint blockade across cancer types.
Nat Med
; 30(3): 797-809, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38429524
10.
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
J Immunother Cancer
; 11(10)2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37857528
11.
Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition.
NPJ Precis Oncol
; 7(1): 127, 2023 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38062117
12.
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Cell Rep Med
; 4(11): 101242, 2023 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37852261
13.
Contrasting effects of sunitinib within in vivo models of metastasis.
Angiogenesis
; 15(4): 623-41, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22843200
14.
Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution.
Cancer Rep (Hoboken)
; 5(2): e1465, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34245134
15.
Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.
Oncology
; 81(2): 135-40, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21985828
16.
The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial.
Endosc Ultrasound
; 10(5): 335-343, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34558422
17.
Do histopathological features of breast cancer in Australian Indigenous women explain the survival disparity? A two decade long study in the Northern Territory.
Asia Pac J Clin Oncol
; 16(6): 348-355, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32573084
18.
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Mol Cancer Ther
; 15(1): 172-83, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26487278
19.
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
Nat Med
; 22(11): 1294-1302, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27748747
20.
Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?
Hepatobiliary Surg Nutr
; 8(5): 546-548, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31673554